Skip to main content
Top

2013 | OriginalPaper | Hoofdstuk

19. Treatment of Congestive Heart Failure

Auteur : Stephen S. Gottlieb, MD

Gepubliceerd in: Essential Cardiology

Uitgeverij: Springer New York

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

The goals of heart failure treatment include both symptomatic improvement and prolongation of life. These goals are not necessarily concordant. Related to this problem is the observation that the acute actions of an intervention may be very different than the chronic effects. When treating heart failure, therefore, one must understand the immediate and long-term desires of a particular patient and the immediate and long-term consequences of one’s therapy. The result is an uncomfortable use of acute treatments known to have adverse consequences when given for a prolonged period and chronic treatments which are counterintuitive. Fortunately, however, congestive heart failure has been well investigated with multiple large studies demonstrating the multiple consequences of many of our standard interventions.
Literatuur
1.
go back to reference Maisel AS, Krishnaswamy P, Nowak RM, et al. Measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.CrossRefPubMed Maisel AS, Krishnaswamy P, Nowak RM, et al. Measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.CrossRefPubMed
2.
go back to reference Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.CrossRefPubMed Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.CrossRefPubMed
3.
go back to reference Gottlieb SS. Traditional diuretics and other diuresing agents. In: Hosepud JD, Greenberg B, editors. Congestive heart failure. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 443. Gottlieb SS. Traditional diuretics and other diuresing agents. In: Hosepud JD, Greenberg B, editors. Congestive heart failure. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 443.
4.
go back to reference Binanay C, Califf RM, Hasselblad V, for the ESCAPE Investigators and ESCAPE Study Coordinators, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625.CrossRefPubMed Binanay C, Califf RM, Hasselblad V, for the ESCAPE Investigators and ESCAPE Study Coordinators, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625.CrossRefPubMed
5.
go back to reference Felker GM, Lee KL, Bull DA, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.CrossRefPubMed Felker GM, Lee KL, Bull DA, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.CrossRefPubMed
6.
go back to reference Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomized controlled trial. Br Heart J. 1994;71:146–50.CrossRefPubMed Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomized controlled trial. Br Heart J. 1994;71:146–50.CrossRefPubMed
7.
go back to reference Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.CrossRefPubMed Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.CrossRefPubMed
8.
go back to reference Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11.CrossRefPubMed Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11.CrossRefPubMed
9.
go back to reference Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7.CrossRefPubMed Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7.CrossRefPubMed
10.
go back to reference Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–53.CrossRefPubMed Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–53.CrossRefPubMed
11.
go back to reference Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.CrossRef Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.CrossRef
12.
go back to reference Costanzo MR, Guglin ME, Saltzberg MT, for the UNLOAD Trial Investigators, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675.CrossRefPubMed Costanzo MR, Guglin ME, Saltzberg MT, for the UNLOAD Trial Investigators, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675.CrossRefPubMed
13.
go back to reference Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Int Med. 1985;103:222–3.CrossRefPubMed Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Int Med. 1985;103:222–3.CrossRefPubMed
14.
go back to reference The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med. 1991;325:293–302. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med. 1991;325:293–302.
15.
go back to reference The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Eng J Med. 1987;316:1429–34.CrossRef The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Eng J Med. 1987;316:1429–34.CrossRef
16.
go back to reference Gottlieb SS, Robinson S, Weir MR, Fisher ML, Krichten CM. Determinants of the renal response to ACE inhibition in patients with congestive heart failure. Am Heart J. 1992;124:131–6.CrossRefPubMed Gottlieb SS, Robinson S, Weir MR, Fisher ML, Krichten CM. Determinants of the renal response to ACE inhibition in patients with congestive heart failure. Am Heart J. 1992;124:131–6.CrossRefPubMed
17.
go back to reference Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet. 2003;362:772–6.CrossRefPubMed Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet. 2003;362:772–6.CrossRefPubMed
18.
go back to reference McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003;362:767–71.CrossRefPubMed McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003;362:767–71.CrossRefPubMed
19.
go back to reference Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.CrossRefPubMed Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.CrossRefPubMed
20.
go back to reference Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–52.CrossRefPubMed Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–52.CrossRefPubMed
21.
go back to reference Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.CrossRefPubMed Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.CrossRefPubMed
22.
go back to reference Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.CrossRefPubMed Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.CrossRefPubMed
23.
go back to reference CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13.CrossRef CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13.CrossRef
24.
go back to reference MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRef MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.CrossRef
25.
go back to reference Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.CrossRefPubMed Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.CrossRefPubMed
26.
go back to reference Hjalmarson Å, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–302.CrossRefPubMed Hjalmarson Å, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295–302.CrossRefPubMed
27.
go back to reference Gottlieb SS, Fisher ML, Kjekshus J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation. 2002;105:1182–8.CrossRefPubMed Gottlieb SS, Fisher ML, Kjekshus J, et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation. 2002;105:1182–8.CrossRefPubMed
28.
go back to reference Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712–8.CrossRefPubMed Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712–8.CrossRefPubMed
29.
go back to reference Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13.CrossRefPubMed Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13.CrossRefPubMed
30.
go back to reference The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.CrossRef The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.CrossRef
31.
go back to reference Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329:1–7.CrossRefPubMed Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993;329:1–7.CrossRefPubMed
32.
go back to reference Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Eng J Med. 1991;325:1468–75.CrossRef Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Eng J Med. 1991;325:1468–75.CrossRef
33.
go back to reference Bardy GH, Lee KL, Mark DB, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225.CrossRefPubMed Bardy GH, Lee KL, Mark DB, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225.CrossRefPubMed
34.
go back to reference McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297(22):2502.CrossRefPubMed McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297(22):2502.CrossRefPubMed
35.
go back to reference Massie BM, Collins JF, Ammon SE, for the WATCH Trial Investigators, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119(12):1616.CrossRefPubMed Massie BM, Collins JF, Ammon SE, for the WATCH Trial Investigators, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 2009;119(12):1616.CrossRefPubMed
36.
go back to reference Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 1996;348:633–8. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet. 1996;348:633–8.
37.
go back to reference Taylor DO, Stehlik J, Edwards LB, et al. Registry of the international society for heart and lung transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant. 2009;28(10):1007.CrossRefPubMed Taylor DO, Stehlik J, Edwards LB, et al. Registry of the international society for heart and lung transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant. 2009;28(10):1007.CrossRefPubMed
38.
go back to reference Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J Heart Lung Transplant. 2006;25(9):1024.CrossRefPubMed Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J Heart Lung Transplant. 2006;25(9):1024.CrossRefPubMed
39.
go back to reference Rose EA, Gelijns AC, Moskowitz AJ, for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435.CrossRefPubMed Rose EA, Gelijns AC, Moskowitz AJ, for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435.CrossRefPubMed
40.
go back to reference Slaughter MS, Rogers JG, Milano CA, for the HeartMate II Investigators, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241.CrossRefPubMed Slaughter MS, Rogers JG, Milano CA, for the HeartMate II Investigators, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241.CrossRefPubMed
41.
go back to reference Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol. 1996;78:966–9.CrossRefPubMed Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol. 1996;78:966–9.CrossRefPubMed
42.
go back to reference Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45(3):381.CrossRefPubMed Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45(3):381.CrossRefPubMed
43.
go back to reference Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–5.CrossRefPubMed Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–5.CrossRefPubMed
44.
go back to reference Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170(6):507.CrossRefPubMed Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170(6):507.CrossRefPubMed
45.
go back to reference Abraham WT, Adamson PB, Bourge RC, for the CHAMPION Trial Study Group, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658.CrossRefPubMed Abraham WT, Adamson PB, Bourge RC, for the CHAMPION Trial Study Group, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658.CrossRefPubMed
46.
go back to reference O’Connor CM, Whellan DJ, Lee KL, for the HF-ACTION Investigators, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439.CrossRefPubMed O’Connor CM, Whellan DJ, Lee KL, for the HF-ACTION Investigators, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439.CrossRefPubMed
47.
go back to reference The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.
48.
go back to reference Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.CrossRefPubMed Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart ­failure: the CHARM-Overall programme. Lancet. 2003;362:759–66.CrossRefPubMed
49.
go back to reference Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMed Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMed
50.
go back to reference Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.CrossRefPubMed Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–95.CrossRefPubMed
go back to reference Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391.CrossRefPubMed Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391.CrossRefPubMed
go back to reference Lindenfeld J, Albert NM, Boehmer JP, Collins SP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1.CrossRefPubMed Lindenfeld J, Albert NM, Boehmer JP, Collins SP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16(6):e1.CrossRefPubMed
Metagegevens
Titel
Treatment of Congestive Heart Failure
Auteur
Stephen S. Gottlieb, MD
Copyright
2013
Uitgeverij
Springer New York
DOI
https://doi.org/10.1007/978-1-4614-6705-2_19